Cardiovascular Toxicity Induced by Vascular Endothelial Growth Factor Inhibitors

Cardiotoxicity is an important side effect of vascular endothelial growth factor (VEGF) inhibitors therapy used in the treatment of various malignancies, leading to increased morbidity and mortality. Arterial hypertension, cardiac ischemia with the acceleration of atherosclerosis, arrhythmias, myocardial dysfunction and thromboembolic disease are the most feared cardiovascular adverse reactions due to VEGF inhibitors. Susceptibility for the occurrence of VEGF inhibitors-induced cardiotoxicity has multifactorial determinants, with a significant inter-individual variation. Baseline cardiovascular risk assessment of the patient, type and stage of cancer, dose and duration of VEGF inhibitors treatment and adjuvant chemotherapy or radiotherapy are the main predictors for cardiotoxicity. The role of the cardio-oncology team becomes essential for achieving maximum therapeutic anti-angiogenic effects with minimum cardiovascular side effects. This review will summarize the incidence, risk factors, mechanisms, management and treatment of VEGF inhibitors-induced cardiovascular toxicity.

• Publication year

  2023

• Venue

  Life

• Publication date

  2023-01-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.3390/life13020366PMID 36836722PMCID 9965690
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ESC guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery: a practical guide for clinicians

  2023cited by this paper
• 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).

  2022cited by this paper
• 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death.

  2022cited by this paper
• Comments on the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure.

  2022cited by this paper
• 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).

  2022influential reference
• 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery.

  2022cited by this paper
• 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)

  2021cited by this paper
• 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.

  2021cited by this paper
• 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS).

  2020cited by this paper
• 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.

  2020cited by this paper
• Commentary: The new ESC guidelines for the diagnosis and management of chronic coronary syndromes.

  2019cited by this paper
• Vascular Cardio-Oncology: Vascular Endothelial Growth Factor inhibitors and hypertension.

  2019influential reference
• [2018 ESC/ESH Guidelines for the management of arterial hypertension].

  2019cited by this paper
• 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes.

  2019cited by this paper
• Acute blood pressure elevation associated with biological therapies for cancer: a focus on VEGF signaling pathway inhibitors

  2019influential reference
• 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)

  2019cited by this paper
• Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors

  2018influential reference
• 2018 ESC/ESH Guidelines for the management of arterial hypertension.

  2018cited by this paper
• Recent Advances

  2018cited by this paper
• Cardiotoxicity with vascular endothelial growth factor inhibitor therapy

  2018cited by this paper
• 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).

  2018cited by this paper
• Vascular toxicities with VEGF inhibitor therapies–focus on hypertension and arterial thrombotic events

  2018cited by this paper
• 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.

  2018cited by this paper
• The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.

  2018cited by this paper
• Tyrosine Kinase Inhibitor-Induced Hypertension

  2018influential reference
• Cardiotoxicity associated with tyrosine kinase-targeted anticancer therapy

  2018influential reference
• Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond.

  2017cited by this paper
• Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review

  2017cited by this paper
• Recent Advances in Hypertension and Cardiovascular Toxicities With Vascular Endothelial Growth Factor Inhibition

  2017influential reference
• Posterior Reversible Encephalopathy Syndrome With Concurrent Nephrotic Syndrome in a Patient Treated With Pazopanib for Metastatic Renal Cell Carcinoma: Case Report and Review of the Literature

  2017influential reference
• Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell Carcinoma

  2017influential reference
• Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a Danish nationwide population‐based cohort study

  2017cited by this paper
• Mechanisms and Genetic Susceptibility of Chemotherapy-Induced Cardiotoxicity in Patients With Breast Cancer

  2017cited by this paper
• 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).

  2016cited by this paper
• Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors

  2016cited by this paper
• Vascular Toxicities of Cancer Therapies: The Old and the New – An Evolving Avenue

  2016cited by this paper
• Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors.

  2016cited by this paper
• Noninvasive Measures of Ventricular-Arterial Coupling and Circumferential Strain Predict Cancer Therapeutics-Related Cardiac Dysfunction.

  2016cited by this paper
• Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors

  2015cited by this paper
• Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia.

  2015cited by this paper
• The Scientific

  2015cited by this paper
• Early detection of epirubicin-induced cardiotoxicity in patients with breast cancer.

  2014cited by this paper
• Approach to the management of incidental venous thromboembolic events in patients with cancer.

  2014cited by this paper
• Sorafenib Cardiotoxicity Increases Mortality After Myocardial Infarction

  2014cited by this paper
• Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: the Cancer-DACUS Study.

  2014cited by this paper
• Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: an up-to-date meta-analysis.

  2014cited by this paper
• Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome.

  2014cited by this paper
• Cancer Therapy–Induced Cardiotoxicity: Basic Mechanisms and Potential Cardioprotective Therapies

  2014cited by this paper
• Systemic VEGF inhibition accelerates experimental atherosclerosis and disrupts endothelial homeostasis--implications for cardiovascular safety.

  2013cited by this paper
• Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales

  2013cited by this paper
• Chemotherapy-induced Cardiotoxicity.

  2013cited by this paper
• Coronary Microvascular Pericytes Are the Cellular Target of Sunitinib Malate–Induced Cardiotoxicity

  2013cited by this paper
• ESH / ESC Guidelines for the management of arterial hypertension

  2013influential reference
• Chemotherapy-Induced Cardiotoxicity

  2012cited by this paper
• Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors.

  2012cited by this paper
• ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

  2011cited by this paper
• Angiogenesis Inhibitors: Current Strategies and Future Prospects

  2010influential reference
• Chemotherapy-induced thrombosis.

  2006cited by this paper

• CMTM6 promotes radioresistance in hepatocellular carcinoma via EMT induction and synergistic interaction with VEGFA

  2026cites this paper
• VEGF Inhibitors in Hematologic Cancers and Hypertension/Cardiac Effects.

  2026cites this paper
• Renal-vascular axis: unmasking its role in vascular endothelial growth factor-inhibitor vascular toxicity in cancer patients.

  2026cites this paper
• Real-world adverse event patterns of ramucirumab in the FAERS database (2014-2024): a comprehensive pharmacovigilance study.

  2026cites this paper
• Cancer Therapy‐Induced Cardiotoxicity: A Narrative Review

  2026cites this paper
• Signals of pericardial and myocardial events associated with antiangiogenic drugs: a disproportionality analysis on FAERS®

  2026cites this paper
• Dual-parameter sequential ultrasound irradiation with oxygen-loaded microbubbles induces vascular normalization to potentiate sonodynamic therapy in breast cancer

  2026cites this paper
• Effect of the Vascular Endothelial Growth Factor Inhibitor Toceranib on Cardiac Function and Endothelial Dysfunction Biomarkers in Dogs With Cancer

  2025cites this paper
• Evolving insights into VEGFI cardiotoxicity: past challenges, present findings and future opportunities

  2025cites this paper
• Left Ventricular Dysfunction Caused by Combined Pembrolizumab and Lenvatinib Following Doxorubicin

  2025cites this paper
• Cardiotoxicity Induced by Anticancer Therapies: A Call for Integrated Cardio-Oncology Practice

  2025cites this paper
• Overlapping risk factors and pathogenic mechanisms in lung cancer and cardiovascular disease

  2025cites this paper
• Cardiotoxicity related to intrapericardial infusion of bevacizumab in the treatment of lung cancer-mediated malignant pericardial effusion: a case report

  2025cites this paper
• Comprehensive risk profiling and long-term cardiovascular toxicity in HER2-positive breast cancer patients treated with trastuzumab

  2025cites this paper
• Long-term administration of multikinase inhibitors is a potential risk factor for atherosclerosis in patients with thyroid cancer.

  2025cites this paper
• Multiscale profiling of tyrosine kinase inhibitor cardiotoxicity reveals mechanosensitive ion channel PIEZO1 as cardioprotective.

  2025cites this paper
• Narrative Literature Review of Cancer Therapy-related Cardiac Dysfunction

  2025cites this paper
• Cardiovascular impacts of combination cancer therapies in Africa: challenges and solutions

  2025cites this paper
• Chemotherapy-Induced Cardiotoxicity: Mechanisms, Detection and Emerging Therapies in Cardio-Oncology

  2025cites this paper
• Caesalpinia sappan L. ethyl acetate extract regulated angiogenesis in atherosclerosis by modulating the miR-126/VEGF signalling pathway

  2025cites this paper
• Anticancer Chemotherapy-Induced Atherosclerotic Cardiovascular Disease: A Comprehensive Review

  2025cites this paper
• Acute vascular and cardiac effects of lenvatinib in mice

  2025cites this paper
• Cardio-oncology: Emerging Concepts in Cardiovascular Sequelae of Cancer Therapies, Translational Research and Reverse Cardio-oncology

  2025cites this paper
• In the Era of Cardiovascular–Kidney–Metabolic Syndrome in Cardio-Oncology: From Pathogenesis to Prevention and Therapy

  2025cites this paper
• How to deal with renal toxicities from immune-based combination treatments in metastatic renal cell carcinoma. A nephrological consultation for Oncologists.

  2024cites this paper
• Cardiovascular challenges in cancer patients treated with vascular endothelial growth inhibitor therapy

  2024cites this paper
• Frequency of ischemic cardiac events in patients receiving long-term multikinase inhibitor: A report of three cases

  2024cites this paper
• Exploring the Spectrum of VEGF Inhibitors’ Toxicities from Systemic to Intra-Vitreal Usage in Medical Practice

  2024cites this paper
• Serum Biomarkers to Dynamically Predict the Risk of Cardiovascular Events in Patients under Oncologic Therapy. A Multicenter Observational Study

  2024cites this paper
• Cardiovascular implications of anti-angiogenic therapeutic agents in cancer patients

  2024cites this paper
• Immune-inflammatory modulation by natural products derived from edible and medicinal herbs used in Chinese classical prescriptions.

  2024cites this paper
• Physiology and functional significance of the coronary microcirculation: An overview of its implications in health and disease

  2024cites this paper
• Cancer knocks you out by fasting: Cachexia as a consequence of metabolic alterations in cancer

  2024cites this paper
• Global Registry of Acute Coronary Events Score Underestimates Post-Acute Coronary Syndrome Mortality among Cancer Patients

  2023cites this paper
• Antineoplastic drugs inducing cardiac and vascular toxicity - An update.

  2023cites this paper